Causes and consequences of inflammation on anemia management in hemodialysis patients

Hemodialysis International

Volumn 13, Issue 2, 2009, Pages 222-234

  Chawla, Lakhmir S ^a   Krishnan, Mahesh ^b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b AMGEN INC   (United States)

Author keywords

Anemia; C reactive protein (CRP); Erythropoiesis stimulatingagents (ESAs); Hemodialysis; Inflammation; Mortality

Indexed keywords

ANTIANEMIC AGENT; C REACTIVE PROTEIN; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; DISEASE MARKER; DOSE RESPONSE; ERYTHROPOIESIS; GENETIC ASSOCIATION; HEART DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; INFECTION; INFLAMMATION; KIDNEY FAILURE; MORTALITY; NEUTROPHIL COUNT; NONHUMAN; OBESITY; PATHOGENESIS; PREVALENCE; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEPTICEMIA;

ANEMIA; COMORBIDITY; HEMATINICS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; PREVALENCE; RENAL DIALYSIS; RISK FACTORS;

EID: 65449126687     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2009.00352.x     Document Type: Review

References (138)

1. USRDS. USRDS 2007 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007.
2. Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif. 2001; 19: 53-61.
3. den Elzen WP, van Manen JG, Boeschoten EW, Krediet RT, Dekker FW. The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis. Nephrol Dial Transplant. 2006; 21: 1588-1595.
4. Honda H, Qureshi AR, Heimburger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis. 2006; 47: 139-148.
5. Menon V, Wang X, Greene T, et al. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis. 2003; 42: 44-52.
6. Racki S, Zaputovic L, Mavric Z, Vujicic B, Dvornik S. C-reactive protein is a strong predictor of mortality in hemodialysis patients. Ren Fail. 2006; 28: 427-433.
7. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35: 469-476.
8. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55: 648-658.
9. Bellomo G, Lippi G, Saronio P, et al. Inflammation, infection and cardiovascular events in chronic hemodialysis patients: A prospective study. J Nephrol. 2003; 16: 245-251.
10. Franek E, Blaschyk R, Kolonko A, et al. Chronic periodontitis in hemodialysis patients with chronic kidney disease is associated with elevated serum C-reactive protein concentration and greater intima-media thickness of the carotid artery. J Nephrol. 2006; 19: 346-351.
11. Gattone M, Iacoviello L, Colombo M, et al. Chlamydia pneumoniae and cytomegalovirus seropositivity, inflammatory markers, and the risk of myocardial infarction at a young age. Am Heart J. 2001; 142: 633-640.
12. Haubitz M, Brunkhorst R. C-reactive protein and chronic Chlamydia pneumoniae infection-long-term predictors for cardiovascular disease and survival in patients on peritoneal dialysis. Nephrol Dial Transplant. 2001; 16: 809-815.
13. Slade GD, Offenbacher S, Beck JD, Heiss G, Pankow JS. Acute-phase inflammatory response to periodontal disease in the US population. J Dent Res. 2000; 79: 49-57.
14. Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000; 35: 537-544.
15. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: A prospective cohort study. Lancet. 1999; 353: 1838-1842.
16. Pecoits-Filho R, Heimburger O, Barany P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003; 41: 1212-1218.
17. Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost. 1995; 73: 374-379.
18. Arizono K, Nomura K, Motoyama T, et al. Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purif. 2004; 22 (Suppl 2): 26-29.
19. Ayus JC, Mizani MR, Achinger SG, Thadhani R, Go AS, Lee S. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: A prospective, controlled study. J Am Soc Nephrol. 2005; 16: 2778-2788.
20. Docci D, Bilancioni R, Buscaroli A, et al. Elevated serum levels of C-reactive protein in hemodialysis patients. Nephron. 1990; 56: 364-367.
21. Furuya R, Kumagai H, Takahashi M, Sano K, Hishida A. Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients. Blood Purif. 2005; 23: 311-316.
22. Gesualdo L, Pertosa G, Grandaliano G, Schena FP. Cytokines and bioincompatibility. Nephrol Dial Transplant. 1998; 13: 1622-1626.
23. Hsu PY, Lin CL, Yu CC, et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients-a prospective cross-over study. J Nephrol. 2004; 17: 693-700.
24. Lonnemann G. When good water goes bad: How it happens, clinical consequences and possible solutions. Blood Purif. 2004; 22: 124-129.
25. Malaponte G, Bevelacqua V, Fatuzzo P, et al. IL-1beta, TNF-alpha and IL-6 release from monocytes in haemodialysis patients in relation to dialytic age. Nephrol Dial Transplant. 2002; 17: 1964-1970.
26. Memoli B, Minutolo R, Bisesti V, et al. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis. 2002; 39: 266-273.
27. Panichi V, Tetta C, Rindi P, Palla R, Lonnemann G. Plasma C-reactive protein is linked to backfiltration associated interleukin-6 production. ASAIO J. 1998; 44: M415-M417.
28. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant. 2002; 17: 1814-1818.
29. Schiffl H, Lang SM, Stratakis D, Fischer R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant. 2001; 16: 1863-1869.
30. Schindler R, Beck W, Deppisch R, et al. Short bacterial DNA fragments: detection in dialysate and induction of cytokines. J Am Soc Nephrol. 2004; 15: 3207-3214.
31. Schindler R, Boenisch O, Fischer C, Frei U. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol. 2000; 53: 452-459.
32. Rao M, Guo D, Perianayagam MC, et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2005; 45: 324-333.
33. Selim G, Stojceva-Taneva O, Zafirovska K, et al. Inflammation predicts all-cause and cardiovascular mortality in haemodialysis patients. Prilozi. 2006; 27: 133-144.
34. Beerenhout CH, Kooman JP, van der Sande FM, Hackeng C, Leunissen KM. C-reactive protein levels in dialysis patients are highly variable and strongly related to co-morbidity. Nephrol Dial Transplant. 2003; 18: 221.
35. van Tellingen A, Grooteman MP, Schoorl M, et al. Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int. 2002; 62: 632-638.
36. Reddan DN, Frankenfield DL, Klassen PS, et al. Regional variability in anaemia management and haemoglobin in the US. Nephrol Dial Transplant. 2003; 18: 147-152.
37. Teruel JL, Marcen R, Ocana J, et al. Clinical significance of C-reactive protein in patients on hemodialysis: A longitudinal study. Nephron Clin Pract. 2005; 100: C140-c145.
38. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis. 1997; 29: 565-568.
39. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999; 33: 63-72.
40. Locatelli F, Andrulli S, Memoli B, et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 2006; 21: 991-998.
41. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-2084.
42. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098.
43. Landray MJ, Wheeler DC, Lip GY, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: The chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis. 2004; 43: 244-253.
44. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003; 107: 87-92.
45. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005; 68: 237-245.
46. Ortega O, Rodriguez I, Gallar P, et al. Significance of high C-reactive protein levels in pre-dialysis patients. Nephrol Dial Transplant. 2002; 17: 1105-1109.
47. Panichi V, Migliori M, De Pietro S, et al. C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron. 2002; 91: 594-600.
48. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999; 55: 1899-1911.
49. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868-874.
50. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998; 32: 107-114.
51. Panichi V, Maggiore U, Taccola D, et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant. 2004; 19: 1154-1160.
52. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant. 2002; 17: 1684-1688.
53. Zoccali C, Mallamaci F, Tripepi G, et al. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med. 2003; 254: 132-139.
54. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. Kidney Int. 1999; 55: 1945-1951.
55. Bradbury BD, Krishnan M, Critchlow CW. Correlation of C-reactive protein (CRP) levels and markers of disease severity in hemodialysis (HD) patients. Presented at the 39th Annual Meeting of the American Society of Nephrology, San Diego, CA, 2006, PO603.
56. Muller J, Nyvad O, Larsen NA, et al. Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in dialysis patients, renal transplant recipients and healthy controls. Scand J Clin Lab Invest. 2002; 62: 503-509.
57. Zoccali C, Mallamaci F, Tripepi G. Atherosclerosis in dialysis patients: Does Chlamydia pneumoniae infection contribute to cardiovascular damage? Nephrol Dial Transplant. 2002; 17 (Suppl 8): 25-28; discussion 40.
58. Chen LP, Chiang CK, Chan CP, Hung KY, Huang CS. Does periodontitis reflect inflammation and malnutrition status in hemodialysis patients? Am J Kidney Dis. 2006; 47: 815-822.
59. Rahmati MA, Craig RG, Homel P, Kaysen GA, Levin NW. Serum markers of periodontal disease status and inflammation in hemodialysis patients. Am J Kidney Dis. 2002; 40: 983-989.
60. Naugle K, Darby ML, Bauman DB, Lineberger LT, Powers R. The oral health status of individuals on renal dialysis. Ann Periodontol. 1998; 3: 197-205.
61. Rayner HC, Pisoni RL, Bommer J, et al. Mortality and hospitalization in haemodialysis patients in five European countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004; 19: 108-120.
62. Colville LA, Lee AH. Retrospective analysis of catheter-related infections in a hemodialysis unit. Infect Control Hosp Epidemiol. 2006; 27: 969-973.
63. Saxena AK, Panhotra BR, Al-Mulhim AS. Vascular access related infections in hemodialysis patients. Saudi J Kidney Dis Transpl. 2005; 16: 46-71.
64. Nassar GM, Fishbane S, Ayus JC. Occult infection of old nonfunctioning arteriovenous grafts: A novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. Kidney Int. (Suppl) 2002; 61: S49-S54.
65. Movilli E, Brunori G, Camerini C, et al. The kind of vascular access influences the baseline inflammatory status and epoetin response in chronic hemodialysis patients. Blood Purif. 2006; 24: 387-393.
66. Adrie C, Pinsky MR. The inflammatory balance in human sepsis. Intensive Care Med. 2000; 26: 364-375.
67. Powe NR, Jaar B, Furth SL, Hermann J, Briggs W. Septicemia in dialysis patients: Incidence, risk factors, and prognosis. Kidney Int. 1999; 55: 1081-1090.
68. Bloembergen WE, Stannard DC, Port FK, et al. Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int. 1996; 50: 557-565.
69. Griendling KK, Alexander RW. Endothelial control of the cardiovascular system: Recent advances. FASEB J. 1996; 10: 283-292.
70. Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991; 88: 4651-4655.
71. Clapp BR, Hingorani AD, Kharbanda RK, et al. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res. 2004; 64: 172-178.
72. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (London). 2000; 98: 531-535.
73. Tedgui A, Mallat Z. Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol Rev. 2006; 86: 515-581.
74. Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1996; 77: 723-727.
75. Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996; 28: 964-971.
76. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation. 2003; 107: 1486-1491.
77. White M, Ducharme A, Ibrahim R, et al. Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: Improvement after short-term inotropic support. Clin Sci (London). 2006; 110: 483-489.
78. Sato Y, Takatsu Y, Kataoka K, et al. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol. 1999; 22: 811-813.
79. Nakanishi I, Moutabarrik A, Okada N, et al. Interleukin-8 in chronic renal failure and dialysis patients. Nephrol Dial Transplant. 1994; 9: 1435-1442.
80. Brockhaus M, Bar-Khayim Y, Gurwicz S, Frensdorff A, Haran N. Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int. 1992; 42: 663-667.
81. Descamps-Latscha B, Herbelin A, Nguyen AT, et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol. 1995; 154: 882-892.
82. van Riemsdijk-van Overbeeke IC, Baan CC, Hesse CJ, et al. TNF-alpha: mRNA, plasma protein levels and soluble receptors in patients on chronic hemodialysis, on CAPD and with end-stage renal failure. Clin Nephrol. 2000; 53: 115-123.
83. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002; 62: 1524-1538.
84. Daichou Y, Kurashige S, Hashimoto S, Suzuki S. Characteristic cytokine products of Th1 and Th2 cells in hemodialysis patients. Nephron. 1999; 83: 237-245.
85. Panichi V, Rizza GM, Taccola D, et al. C-reactive protein in patients on chronic hemodialysis with different techniques and different membranes. Biomed Pharmacother. 2006; 60: 14-17.
86. Haubitz M, Brunkhorst R, Wrenger E, Froese P, Schulze M, Koch KM. Chronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis therapy. Perit Dial Int. 1996; 16: 158-162.
87. Honkanen E, Gronhagen-Riska C, Teppo AM, Maury CP, Meri S. Acute-phase proteins during hemodialysis: Correlations with serum interleukin-1 beta levels and different dialysis membranes. Nephron. 1991; 57: 283-287.
88. Macintyre SS. Regulated export of a secretory protein from the ER of the hepatocyte: A specific binding site retaining C-reactive protein within the ER is downregulated during the acute phase response. J Cell Biol. 1992; 118: 253-265.
89. Vaslaki LR, Berta K, Major L, et al. On-line hemodiafiltration does not induce inflammatory response in end-stage renal disease patients: Results from a multicenter cross-over study. Artif Organs. 2005; 29: 406-412.
90. Pedersen M, Bruunsgaard H, Weis N, et al. Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev. 2003; 124: 495-502.
91. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 2002; 105: 804-809.
92. Axelsson J, Rashid Qureshi A, Suliman ME, et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr. 2004; 80: 1222-1229.
93. Pankow JS, Folsom AR, Cushman M, et al. Familial and genetic determinants of systemic markers of inflammation: The NHLBI family heart study. Atherosclerosis. 2001; 154: 681-689.
94. Westendorp RG, Langermans JA, Huizinga TW, Verweij CL, Sturk A. Genetic influence on cytokine production in meningococcal disease. Lancet. 1997; 349: 1912-1913.
95. Girndt M, Kaul H, Sester U, et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int. 2002; 62: 949-955.
96. Girndt M, Sester U, Sester M, et al. The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. Kidney Int. 2001; 60: 2385-2391.
97. Balakrishnan VS, Guo D, Rao M, et al. Cytokine gene polymorphisms in hemodialysis patients: Association with comorbidity, functionality, and serum albumin. Kidney Int. 2004; 65: 1449-1460.
98. Losito A, Kalidas K, Santoni S, Jeffery S. Association of interleukin-6 -174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int. 2003; 64: 616-622.
99. Claus DR, Osmand AP, Gewurz H. Radioimmunoassay of human C-reactive protein and levels in normal sera. J Lab Clin Med. 1976; 87: 120-128.
100. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340: 448-454.
101. Yue CC, Muller-Greven J, Dailey P, Lozanski G, Anderson V, Macintyre S. Identification of a C-reactive protein binding site in two hepatic carboxylesterases capable of retaining C-reactive protein within the endoplasmic reticulum. J Biol Chem. 1996; 271: 22245-22250.
102. Wanner C, Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant. 2002; 17 (Suppl 8): 29-32; discussion 9-40.
103. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107: 499-511.
104. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005; 45 (Suppl 3): S1-S153.
105. Boenisch O, Ehmke KD, Heddergott A, Naoum C, Frei U, Schindler R. C-reactive-protein and cytokine plasma levels in hemodialysis patients. J Nephrol. 2002; 15: 547-551.
106. Horl WH, Jacobs C, Macdougall IC, et al. European best practice guidelines 14-16: Inadequate response to epoetin. Nephrol Dial Transplant. 2000; 15 (Suppl 4): 43-50.
107. Nascimento MM, Pecoits-Filho R, Qureshi AR, et al. The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: A prospective study. Nephrol Dial Transplant. 2004; 19: 2803-2809.
108. Korevaar JC, van Manen JG, Dekker FW, de Waart DR, Boeschoten EW, Krediet RT. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol. 2004; 15: 2916-2922.
109. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003; 108: 1930-1932.
110. Hatanaka K, Li XA, Masuda K, Yutani C, Yamamoto A. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method. Pathol Int. 1995; 45: 635-641.
111. Kobayashi S, Inoue N, Ohashi Y, et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: Important role of C-reactive protein. Arterioscler Thromb Vasc Biol. 2003; 23: 1398-1404.
112. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001; 158: 1039-1051.
113. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998; 18: 1386-1392.
114. Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive protein distribution: Its relation to development of atherosclerosis. Atherosclerosis. 1999; 145: 375-379.
115. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998; 98: 839-844.
116. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005; 352: 29-38.
117. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352: 20-28.
118. Mason NA, Bailie GR, Satayathum S, et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis. 2005; 45: 119-126.
119. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002; 61: 297-304.
120. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353: 238-248.
121. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant. 2002; 17: 1513-1517.
122. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int. 2003; 64: 1514-1521.
123. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis. 2003; 42: 761-773.
124. Bratosin D, Mazurier J, Tissier JP, et al. Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages. A Rev Biochim. 1998; 80: 173-195.
125. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992; 79: 1987-1994.
126. Goicoechea M, Martin J, de Sequera P, et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int. 1998; 54: 1337-1343.
127. Stenvinkel P. Anaemia and inflammation: What are the implications for the nephrologist? Nephrol Dial Transplant. 2003; 18 (Suppl 8): viii17-viii22.
128. Trey JE, Kushner I. The acute phase response and the hematopoietic system: The role of cytokines. Crit Rev Oncol Hematol. 1995; 21: 1-18.
129. Feelders RA, Vreugdenhil G, Eggermont AM, Kuiper-Kramer PA, van Eijk HG, Swaak AJ. Regulation of iron metabolism in the acute-phase response: Interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest. 1998; 28: 520-527.
130. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ. Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant. 1998; 13: 82-88.
131. Fahmy M, Young SP. Modulation of iron metabolism in monocyte cell line U937 by inflammatory cytokines: Changes in transferrin uptake, iron handling and ferritin mRNA. Biochem J. 1993; 296 (Part 1): 175-181.
132. Jurado RL. Iron, infections, and anemia of inflammation. Clin Infect Dis. 1997; 25: 888-895.
133. Pietrangelo A, Trautwein C. Mechanisms of disease: The role of hepcidin in iron homeostasis-implications for hemochromatosis and other disorders. Nat Clin Pract Gastroenterol Hepatol. 2004; 1: 39-45.
134. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113: 1271-1276.
135. Costa E, Lima M, Alves JM, et al. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol. 2008; 28: 268-275.
136. Almond MK, Tailor D, Marsh FP, Raftery MJ, Cunningham J. Increased erythropoietin requirements in patients with failed renal transplants returning to a dialysis programme. Nephrol Dial Transplant. 1994; 9: 270-273.
137. Eschbach JW, Adamson JW. Recombinant human erythropoietin: Implications for nephrology. Am J Kidney Dis. 1988; 11: 203-209.
138. Muirhead N, Hodsman AB. Occult infection and resistance of anaemia to rHuEpo therapy in renal failure. Nephrol Dial Transplant. 1990; 5: 232-234.